-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300

Benzinga·10/12/2026 12:10:01
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.